New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
07:05 EDTOMEROmeros' OMS824 for brain diseases shows positive Phase 2a results
Omeros announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50% higher plasma concentrations than did the previously reported highest dose and had a similar side-effect profile to those of the lower doses. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease. OMS824 was tolerated with mild or moderate adverse events that were consistent with those seen in previous cohorts, were self-limited and did not result in any discontinuation of the drug. An additional PET trial cohort is planned in the coming weeks.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:16 EDTOMEROn The Fly: Pre-market Movers
Subscribe for More Information
07:02 EDTOMEROmeros reports OMS721 inhibits thrombus formation in sera from aHUS patients
Subscribe for More Information
November 13, 2014
08:16 EDTOMEROmeros price target raised to $28 from $20 at Maxim
Maxim raised its price target for Omeros shares to $28 citing better than expected pricing for Omidria. The firm believes global sales of the drug could reach north of $400M by 2017 and keeps a Buy rating on Omeros.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use